>> A company with a significant burn rate will simply run out of cash <<
This story gets popular, once every five years or so. The sector is 25 years old, and it simply happens on rare occasion.
Enabling patents and preclinical research have value. On occasion (e.g., '93-'94, summer '98, and, IMO, the present), they are discounted.
>> 2) the lack of biotech product advancement <<
Are you talking recent, highly publicized product failures and/or problems with FDA, or are you wading in dogma? A wide variety of first-in-class medicines has been approved and marketed. Others are, of course, in advanced clinical testing.
Biotech investors, given time and expertise, generally do quite well. If you have no scientific expertise and don't follow anyone with such, then you shouldn't invest in the sector. Most companies will fail to thrive.
The first of the "genomics derived" products are already approved, and many more are advancing in clinical trials. Toni Clarke's article is, IMO, filled with dogma and fluff crap. |
